RESEARCH TRIANGLE PARK, NC--(Marketwire - February 3, 2009) - Pharmaceutical business
intelligence firm Cutting Edge Information today released a groundbreaking
report that analyzes the fast-growing neurodegenerative disease landscape.
"Neurodegenerative Market Forecast to 2013"
(
http://www.cuttingedgeinfo.com/neurodegenerative) examines key trends
currently affecting the neurodegenerative disease landscape and their
impact on drug development and sales leading into the next decade.
Although several diseases comprise the neurodegenerative field, the report
focuses on Alzheimer's Disease, multiple sclerosis and Parkinson's Disease,
the three illnesses that garner the most research and attention. The
report details the historical, current and forecasted performance of 40
drugs -- marketed brands and pipeline products -- within these indications.
The report breaks data down by individual drug and by class. Besides
providing in-depth discussions of each product, analysis compares data
across brands and across classes -- leading to an honest and accurate
evaluation of product/class performance: advantages, potential pitfalls,
competitive threats, and clinical successes and failures. The study also
gives insights on which pharma industry leaders are on track to dominate
the markets' space.
"Patients with neurodegenerative diseases have few treatment options, and
many of them are only marginally effective," said Jeremy Spivey, the
report's lead author. "Companies that can make significant inroads with
successful innovative treatments stand to earn billions in revenue. Our
report gives them a strong foundation to understand the market and make
decisions."
In developing this report, CEI analysts considered neurodegenerative drugs
that are expected to earn more than $50 million in any one of the next five
years. Drug classes within the report include:
Alzheimer's: acetylcholinesterase inhibitors, NMDA antagonists, and
amyloid beta therapies
Multiple Sclerosis: interferon betas, immunomodulators, monoclonal
antibodies
Parkinson's: dopaminergic drugs
The 201-page report (
http://www.cuttingedgeinfo.com/neurodegenerative)
consists of 40 brand profiles. These brand snapshots detail products'
competitive and strategic positioning, market opportunities, and patent and
litigation data. They include the following information:
-- Drug's current and projected competitive strength
-- Current/projected sales position within its class
-- Sales projection charts for the next four to seven years
-- Assessment of competition
-- Materiality charts
-- Clinical trial information
"Neurodegenerative Market Forecast to 2013"
(
http://www.cuttingedgeinfo.com/neurodegenerative) is the third Cutting
Edge Information report providing market forecasts for therapeutic areas.
Other reports focus on the oncology and diabetes markets.
Contact Information: CONTACT INFORMATION:
Jeremy Spivey
919-433-0373